Infection rates were similar in patients treated with intravenous immunoglobulin (IVIG) whether they were dosed traditionally or with a precision-dosing strategy, according to a study involving 209 individuals. Moreover, precision-dosing was less costly. Participants received IVIG using either a traditional (n=125) or precision (n=84) dosing strategy. Investigators looked at 30- and 60-day infection rates, immunoglobulin G level response, and IVIG savings. Among the results:
- 30-day infection rate in each cohort was 16%.
- 60-day infection rates were not significantly different (23% in the traditional dosing group and 20% in the precision-dosing contingent).
- Each group experienced an 86% treatment response rate.
- Precision-dosing led to $2,600/month in institutional savings.
The authors estimated that complete adherence to a precision-dosing strategy would lead to an additional $4,600/month in savings.
Stump S, Schepers A, Jones A, Alexander M, Auten J. Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. [Published online ahead of print October 13, 2017]. Pharmacotherapy. doi:10.1002/phar.2047.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al